Wells Fargo & Company Relmada Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding RLMD
# of Institutions
81Shares Held
12.3MCall Options Held
229KPut Options Held
138K-
Franklin Resources Inc San Mateo, CA1.3MShares$3.54 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.42 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$3.23 Million0.01% of portfolio
-
Parsons Capital Management Inc1MShares$2.73 Million0.21% of portfolio
-
Palo Alto Investors LP Palo Alto, CA732KShares$1.99 Million0.33% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $77.8M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...